
Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors: More Common than We Thought
Author(s) -
Salinas Carlos,
Samtani Suraj,
Burotto Mauricio
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13588
Subject(s) - medicine , adrenal insufficiency , primary adrenal insufficiency , immunotherapy , incidence (geometry) , adverse effect , immune system , population , intensive care medicine , pediatrics , immunology , oncology , optics , physics , environmental health
Immunotherapy has changed the treatment landscape for cancer patients; however, immune‐related adverse events, such as primary and secondary adrenal insufficiency, can be life threatening, with potential differences in population incidence. This letter to the editor reports a real‐world experience of Hispanic/Latino patients treated with immunotherapy and the incidence of adrenal insufficiency.